Albany Molecular Research Financial Statements
Albany Molecular Research Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Albany Molecular Research Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 192.5 | 179.8 | 183.9 |
| Gross Profit ($ mil.) | 60.5 | 51.2 | 69.2 |
| Operating Income ($ mil.) | 11.4 | (0.9) | 23.5 |
| Total Net Income ($ mil.) | 8.9 | 2.2 | 16.3 |
| Diluted EPS (Net Income) | 0.27 | 0.07 | 0.50 |
Albany Molecular Research Quarterly Statements
| Quarter Ending Jun 08 | Quarter Ending Mar 08 | Quarter Ending Dec 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 57.9 | 53.6 | 47.2 |
| Gross Profit ($ mil.) | 24.4 | 17.3 | 13.4 |
| Operating Income ($ mil.) | 9.0 | 4.3 | (1.3) |
| Total Net Income ($ mil.) | 5.7 | 4.7 | (0.8) |
| Diluted EPS (Net Income) | 0.18 | 0.15 | (0.03) |
Albany Molecular Research Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 2.70 | 1.41 | 1.55 |
| Price/Earnings Ratio | 47.49 | 21.89 | 15.75 |
| Price/Book Ratio | 1.69 | 2.79 | 1.49 |
| Price/Cash Flow Ratio | 26.96 | 14.19 | 9.68 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Albany Molecular Research Financial Ratios
Albany Molecular Research Competitive Intelligence
| Charles River Laboratories | Covance | PAREXEL | |
|---|---|---|---|
| Annual Sales ($ mil.) | 1,230.6 | 1,631.5 | 918.1 |
| Employees | 8,500 | 8,700 | -- |
| Market Cap ($ mil.) | 4,609.5 | 6,111.9 | 1,861.1 |
Competitive Landscape
